Shares in UK biotech firm Circassia Pharmaceuticals PLC jumped by as much as 30% to 114 pence on the LSE on Mar. 17 on news that it had entered into a deal with AstraZeneca PLC to secure certain US commercial rights to two chronic obstructive pulmonary disease products (COPD), Tudorza (aclidinium bromide) and Duaklir (aclidinium bromide plus formoterol), for up $230m.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?